-----BEGIN PRIVACY-ENHANCED MESSAGE-----
Proc-Type: 2001,MIC-CLEAR
Originator-Name: webmaster@www.sec.gov
Originator-Key-Asymmetric:
 MFgwCgYEVQgBAQICAf8DSgAwRwJAW2sNKK9AVtBzYZmr6aGjlWyK3XmZv3dTINen
 TWSM7vrzLADbmYQaionwg5sDW3P6oaM5D3tdezXMm7z1T+B+twIDAQAB
MIC-Info: RSA-MD5,RSA,
 E6yV31Aagk8wO2/iMpmyXy8rX9hcDlhLXnzcF8q9oXzCafRkWK+R+Qtf1tGxcfgz
 trdSFjT8PvXDi/Ze32PAwQ==

<SEC-DOCUMENT>0000911916-09-000092.txt : 20090605
<SEC-HEADER>0000911916-09-000092.hdr.sgml : 20090605
<ACCEPTANCE-DATETIME>20090605131418
ACCESSION NUMBER:		0000911916-09-000092
CONFORMED SUBMISSION TYPE:	SC 13D/A
PUBLIC DOCUMENT COUNT:		2
FILED AS OF DATE:		20090605
DATE AS OF CHANGE:		20090605

FILED BY:		

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			KISSINGER PETER
		CENTRAL INDEX KEY:			0001053615

	FILING VALUES:
		FORM TYPE:		SC 13D/A

	MAIL ADDRESS:	
		STREET 1:		111 LORENE PLACE
		CITY:			WEST LAFAYETTE
		STATE:			IN
		ZIP:			47906

SUBJECT COMPANY:	

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			BIOANALYTICAL SYSTEMS INC
		CENTRAL INDEX KEY:			0000720154
		STANDARD INDUSTRIAL CLASSIFICATION:	SERVICES-COMMERCIAL PHYSICAL & BIOLOGICAL RESEARCH [8731]
		IRS NUMBER:				351345024
		STATE OF INCORPORATION:			IN
		FISCAL YEAR END:			0930

	FILING VALUES:
		FORM TYPE:		SC 13D/A
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	005-52991
		FILM NUMBER:		09876379

	BUSINESS ADDRESS:	
		STREET 1:		2701 KENT AVE
		CITY:			WEST LAFAYETT
		STATE:			IN
		ZIP:			47906-1382
		BUSINESS PHONE:		3174634527

	MAIL ADDRESS:	
		STREET 1:		2701 KENT AVENUE
		CITY:			WEST LAFAYETTE
		STATE:			IN
		ZIP:			47906-1382
</SEC-HEADER>
<DOCUMENT>
<TYPE>SC 13D/A
<SEQUENCE>1
<FILENAME>kissinger_13d.txt
<TEXT>

                                  UNITED STATES
                       SECURITIES AND EXCHANGE COMMISSION
                             Washington, D.C. 20549

                                  SCHEDULE 13D

                    Under the Securities Exchange Act of 1934
                               (Amendment No. 1)*



                           Bioanalytical Systems, Inc.
- -------------------------------------------------------------------------------
                                (Name of Issuer)

                                  Common Shares
- -------------------------------------------------------------------------------
                         (Title of Class of Securities)

                                   09058M 10 3
- -------------------------------------------------------------------------------
                                 (CUSIP Number)

                            Peter T. Kissinger, Ph.D.
                                111 Lorene Place
                          West Lafayette, IN 47906-8620

                                    Copy to:
                               James A. Aschleman
                               Baker & Daniels LLP
                          900 E. 96th Street, Suite 600
                             Indianapolis, IN 46240

- -------------------------------------------------------------------------------
           (Name, Address and Telephone Number of Person Authorized to
                       Receive Notices and Communications)

                                  June 5, 2009
- -------------------------------------------------------------------------------
              (Date of Event which Requires Filing of this Statement)

     If the filing person has previously filed a statement on Schedule
     13G to report the acquisition that is the subject of this Schedule
     13D, and is filing this schedule because of Sections 240.13d-l(e),
     240.13d-l(f) or 240.13d-1(g), check the following box. |X|

     Note: Schedules filed in paper format shall include a signed
     original and five copies of the schedule, including all exhibits.
     See Section 240.13d-7 for other parties to whom copies are to be sent.

     * The remainder of this cover page shall be filled out for a
     reporting person's initial filing on this form with respect to the
     subject class of securities, and for any subsequent amendment
     containing information which would alter disclosures provided in a
     prior cover page.

     The information required on the remainder of this cover page shall
     not be deemed to be "filed" for the purpose of Section 18 of the
     Securities Exchange Act of 1934 ("Act") or otherwise subject to the
     liabilities of that section of the Act but shall be subject to all
     other provisions of the Act (however, see the Notes).


<PAGE>



CUSIP No.  09058M 10 3
- -------------------------------------------------------------------------------

1. Name of Reporting Person.
   Peter T. Kissinger, Ph.D.
- -------------------------------------------------------------------------------

2. Check the Appropriate Box if a Member of a Group (See Instructions)

   (a)      |X|

   (b)      |_|
- -------------------------------------------------------------------------------

3. SEC Use Only
- -------------------------------------------------------------------------------

4. Source of Funds (See Instructions): PF (see Item 3)
- -------------------------------------------------------------------------------

5. Check if Disclosure of Legal Proceedings Is Required Pursuant to
   Items 2(d) or 2(e) |_|
- -------------------------------------------------------------------------------

6. Citizenship or Place of Organization:  United States
- -------------------------------------------------------------------------------

Number of         7.  Sole Voting Power          427,747
Shares            -----------------------------------------------------
Beneficially
Owned by Each     8.  Shared Voting Power        848,220 (1)
Reporting         -----------------------------------------------------
Person With
                  9.  Sole Dispositive Power     427,747
                  -----------------------------------------------------

                  10. Shared Dispositive Power   848,220 (1)
- -----------------------------------------------------------------------

11. Aggregate Amount Beneficially Owned by Each Reporting Person: 1,275,967 (1)
- -------------------------------------------------------------------------------

12. Check if the Aggregate Amount in Row (11) Excludes Certain Shares
    (See Instructions)       |_|
- -------------------------------------------------------------------------------

13. Percent of Class Represented by Amount in Row (11):  26.0% (1)(2)
- -------------------------------------------------------------------------------

14. Type of Reporting Person (See Instructions) IN
- -------------------------------------------------------------------------------
- ----------
(1) Dr. Kissinger shares voting and dispositive power over these shares with
    his spouse. Includes 1,354 shares indirectly held by Ms. Kissinger as
    custodian for the benefit of their children.
(2) Based on 4,915,318 of the Company's Common Shares which were outstanding
    as of May 1, 2009.



<PAGE>



CUSIP No.  09058M 10 3
- -------------------------------------------------------------------------------

1. Name of Reporting Person.
   Candice B. Kissinger
- -------------------------------------------------------------------------------

2. Check the Appropriate Box if a Member of a Group (See Instructions)

   (a)      |X|

   (b)      |_|
- -------------------------------------------------------------------------------

3. SEC Use Only
- -------------------------------------------------------------------------------

4. Source of Funds (See Instructions): PF (see Item 3)
- -------------------------------------------------------------------------------

5. Check if Disclosure of Legal Proceedings Is Required Pursuant to
   Items 2(d) or 2(e) |_|
- -------------------------------------------------------------------------------

6. Citizenship or Place of Organization:  United States
- -------------------------------------------------------------------------------

Number of         7.  Sole Voting Power           252,310 (1)
Shares            -----------------------------------------------------
Beneficially
Owned by Each     8.  Shared Voting Power         1,023,657 (2)
Reporting         -----------------------------------------------------
Person With
                  9.  Sole Dispositive Power      252,310 (1)
                  -----------------------------------------------------

                  10. Shared Dispositive Power    1,023,657 (2)
- -----------------------------------------------------------------------

11. Aggregate Amount Beneficially Owned by Each Reporting Person:
    1,275,967 (1)(2)
- -------------------------------------------------------------------------------

12. Check if the Aggregate Amount in Row (11) Excludes Certain Shares
    (See Instructions)             |_|
- -------------------------------------------------------------------------------

13. Percent of Class Represented by Amount in Row (11):   26.0% (1)(2)(3)
- -------------------------------------------------------------------------------

14. Type of Reporting Person (See Instructions) IN
- -------------------------------------------------------------------------------
- ----------
(1) Includes 1,354 shares indirectly held by Ms. Kissinger as custodian for
    the benefit of their children.
(2) Ms. Kissinger shares voting and dispositive power over these shares with
    her spouse.
(3) Based on 4,915,318 of the Company's Common Shares which were outstanding
    as of May 1, 2009.




<PAGE>


                                Explanatory Note

        This statement constitutes Amendment No. 1 to the Schedule 13D filed
by Peter T. Kissinger, Ph.D. and Candice B. Kissinger (collectively, the
"Kissingers") on April 6, 2009.  Except as specifically set forth herein, the
Schedule 13D remains unmodified.

        Item 4 is hereby amended to add the following:

Item 4. Purpose of Transaction

        On June 5, 2009, the Kissingers provided a follow-up letter dated
June 5, 2009 (the "Letter") to the Board of Directors of Bioanalytical
Systems, Inc. (the "Issuer"). The Letter set forth the biographical information
for the three director candidates proposed by the Kissingers to replace three
of the current members of the Issuer's Board of Directors. The Letter also
indicated that, after reviewing the Schedule 13D/A filed by Thomas A. Harenburg
on May 14, 2009, the Kissingers support Jerome G. Marchant, the director
candidate proposed by Mr. Harenburg, replacing another current member of the
Issuer's Board of Directors.  A copy of the Letter is filed herewith and
attached hereto as Exhibit 99.3 and incorporated herein by reference. Any
descriptions herein of the Letter are qualified in their entirety by reference
to the Letter.

        Item 7 is hereby amended to add the following exhibit:

Item 7.  Material to Be Filed as Exhibits

         Exhibit 99.3 - Letter from Peter T.  Kissinger, Ph.D. and
Candice B. Kissinger  to the Board of  Directors  of  Bioanalytical Systems,
Inc., dated June 5, 2009


- -------------------------------------------------------------------------------


<PAGE>



                                    SIGNATURES

         After reasonable inquiry and to the best of my knowledge and belief,
I certify that the information set forth in this statement is true, complete
and correct.



Dated:  June 5, 2009



By:    /s/  Peter T. Kissinger, Ph.D.
     ---------------------------------------

         Peter T. Kissinger, Ph.D.



By:    /s/  Candice B. Kissinger
     ---------------------------------------

         Candice B. Kissinger

</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99
<SEQUENCE>2
<FILENAME>kissinger_ex3.txt
<TEXT>


Exhibit 99.3

Letter from Peter T. Kissinger, Ph.D. and Candice B. Kissinger to the
Board of Directors of Bioanalytical Systems, Inc.




                             PETER T. KISSINGER, PH.D. AND CANDICE B. KISSINGER
                                                               111 Lorene Place
                                             West Lafayette, Indiana 47906-8620

June 5, 2009

Board of Directors of Bioanalytical Systems, Inc.
c/o Corporate Secretary, Bioanalytical Systems, Inc.
2701 Kent Avenue
West Lafayette, IN 47906

Dear Sirs:

         As a supplement to our letter dated April 6, 2009, we are again
requesting that the Board of Directors of Bioanalytical Systems, Inc.
(the "Company") agree to promptly replace three of the current members of the
Board with our director nominees - John Landis, Ph.D., Joseph H. Broecker and
Candice B. Kissinger.  Below is the biographical information for each of these
director nominees.

         John Landis, Ph.D. served as Senior Vice President, Pharmaceutical
Sciences of Schering-Plough Corporation, a pharmaceutical company, from
September 2003 until his retirement in October 2008.  In that role, Dr. Landis
led the global pharmaceutical sciences function of pharmacy, analytical
chemistry, process chemistry, biotechnology, quality assurance, clinical
supplies and devices.  Prior to that, Dr. Landis served as Senior Vice
President, Preclinical Development at Pharmacia Corporation from 1997 until
2003 and led the global preclinical functions of toxicology, drug metabolism
and pharmacokinetics, pharmaceutical sciences, analytical chemistry and
laboratory animal care.  Dr. Landis also served as Vice President, Central
Nervous System (CNS) Psychiatry, Critical Care and Inflammation Development
for Pharmacia & Upjohn from 1995 through 1997.  Prior to that, Dr. Landis
was employed by The Upjohn Company, where he held positions of increasing
responsibility in the areas of analytical research, quality assurance and
quality control. He is a current member of Purdue University's Chemistry
Leadership Council and Dean's Leadership Council for the School of Science
and serves on the Advisory Board of South West Michigan Life Science Venture
Capital and on the board of directors of Metabolic Solutions Development
Company.  Over his career, Dr. Landis served on several other boards of
directors, academic advisory panels and professional boards.  Dr. Landis earned
Ph.D. and M.S. degrees in Analytical Chemistry from Purdue University and a
B.S. degree in Chemistry from Kent State University.

         Joseph H. Broecker co-founded Periculum Capital Company, LLC, an
investment banking firm, in 1998 and serves as Senior Managing Director and
head of the firm's private equity and merchant banking practice.  Prior to
that, Mr. Broecker served as Senior Vice President and Managing Director of
NatCity Investments, Inc., as well as its predecessor firm, Raffensperger,
Hughes and Co.  Mr. Broecker co-founded two venture capital private equity
partnerships and remains an active advisor to private equity firms throughout
the Midwest.  Earlier in his career, Mr. Broecker served as a senior operating
and corporate executive of Boehringer Mannheim GmbH, a European-based
multi-national medical device and pharmaceutical company, and was a manager
in the consulting division of Ernst and Young (a/k/a Ernst & Ernst).
Mr. Broecker is a Certified Public Accountant and has served as a director of
a number of private and public companies primarily involved in the healthcare,
chemical and consumer industries.  He graduated from the Executive Program at
Indiana University and earned a B.B.A. in accounting and finance from the
University of Notre Dame.

         Candice B. Kissinger has served as the Legacy Products Coordinator at
The Chao Center, a subsidiary of the Purdue Research Foundation, since
August 2007, where she oversees the North American supply and support of the
prescription antibiotic Seromycin(R).  As an adjunct Associate Professor of
Industrial and Physical Pharmacy at Purdue University since October 2007 and
a faculty member with the Bindley Biosciences Center at Purdue since

<page>

May 2009, she conducts research on new treatments for latent and active
tuberculosis (TB), with special emphasis on new drug formulations suitable for
infants and young children.  Prior to joining The Chao Center, Ms. Kissinger
worked at the Company for 29 years, serving in multiple positions, most
recently as Senior Vice President of Research from January 2000 until June
2007.  During her tenure, Ms. Kissinger obtained seven U.S. and international
patents for Company products, including the Culex(R) Automated Blood Sampler.
Ms. Kissinger also was a member of the Company's board of directors and served
as the Corporate Secretary of the Company from November 1978 until
September 2007.  Prior to joining the Company, she was a researcher in the
Fermentation group, Fine Chemical Division of The Upjohn Company from
1975 until 1978, where she earned her first eight patents. Ms. Kissinger
earned a M.S. degree in Food Science/Industrial Microbiology from the
University of Massachusetts and a B.A. degree in Bacteriology from
Ohio Wesleyan University.

         In addition, after reviewing the Schedule 13D/A filed by
Thomas A. Harenburg on May 14, 2009, we are in support of Jerome G. Marchant,
the director nominee proposed by Mr. Harenburg, promptly replacing another
current member of the Board.

         If the Board fails to honor these requests or any of the other
requests set forth in our prior letter, we reserve the right to take any and
all further action.


Sincerely,

/s/  Peter T. Kissinger, Ph.D.                /s/  Candice B. Kissinger

Peter T. Kissinger, Ph.D.                     Candice B. Kissinger
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
-----END PRIVACY-ENHANCED MESSAGE-----
